Missi finished with 14 points (7-11 FG), 14 rebounds and three blocks across 29 minutes during Monday's 143-130 victory over the Bulls.
Findings from the phase 3 MATTERHORN trial supported the FDA approval of perioperative durvalumab for resectable gastric and GEJ cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback